ASX
LCT 0.115   Last updated 5.23 am
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Target product profile

NTCELL® is expected to be indicated for restoration of function and slowing of disease progression in patients with middle stage Parkinson’s disease experiencing reduced response to standard medical therapy – any one of the following:
                                -  "On" time characterised by dyskinesias (or other non-motor side effects)
                                -  "Off" time characterised by tremor, rigidity, or akinesia/bradykinesia.
                                -  "On/Off" motor fluctuations. 

PRINT PAGE
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.